Alloplex’s abstract has been accepted for a poster presentation.
Abstract (632) – Clinical update from a Phase 1, First-in-Human, Open-label Single Agent Study of SUPLEXA Therapeutic Cells in Patients with Metastatic Solid Tumours and Haematologic Malignancies.
As the largest conference focused solely on cancer immunotherapy, the Society for Immunotherapy of Cancer (‘SITC’)’s annual meeting and pre-conference programs provides international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients.